Ann Surg Oncol

1. BARTLETT EK, Barker CA
   Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial.
   Ann Surg Oncol. 2026 Jun 4. doi: 10.1245/s10434-026-19938.
   

   >> Share

   
   
2. DEVIREDDY A, Yi Y, Nordlund KN, Lin R, et al
   ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with Microsatellitosis.
   Ann Surg Oncol. 2026 May 31. doi: 10.1245/s10434-026-19886.
   

   >> Share

   
   
3. HIEKEN TJ, Flotte TJ, Zahrieh D, Johnson JE, et al
   Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy.
   Ann Surg Oncol. 2026 May 30. doi: 10.1245/s10434-026-19899.
   

   >> Share

   
   

   
   BMC Cancer

4. SHI C, Duan M, Li J, Zhang F, et al
   Pan-cancer atlas of ITGA6 unveils its multifaceted oncogenic roles and therapeutic potential in uveal melanoma.
   BMC Cancer. 2026 Jun 1. doi: 10.1186/s12885-026-16287.
   

   >> Share

   
   

   
   Br J Dermatol

5. DE GIORGI V, Perillo G, Cecchi G, Fazzari F, et al
   Melanoma of unknown primary: UV-driven genomics and the need for era-adjusted outcomes.
   Br J Dermatol. 2026 Jun 1:ljag224. doi: 10.1093.
   

   >> Share

   
   

   
   J Am Acad Dermatol

6. BRODELL RT
   JAAD Game Changers: "External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database".
   J Am Acad Dermatol. 2026 Jun 2:S0190-9622(26)02795.
   

   >> Share

   
   
7. BRODELL RT
   JAAD Game Changers: "RNA analysis of tape strips to rule out melanoma in lesions clinically assessed as cutaneous malignant melanoma: A diagnostic study".
   J Am Acad Dermatol. 2026 Jun 1:S0190-9622(26)02797.
   

   >> Share

   
   
8. ISLAM RK, Shami MZ, Malek AJ, Delahoussaye W, et al
   No difference in recurrence rates between wide local excision and amputation for acral lentiginous melanoma: A systematic review and meta-analysis.
   J Am Acad Dermatol. 2026 Jun 1:S0190-9622(26)02791.
   

   >> Share

   
   
9. LIPNER SR
   Highlights from JAAD Reviews: Geographic and racial disparities in melanoma outcomes.
   J Am Acad Dermatol. 2026 May 29:S0190-9622(26)02782.
   

   >> Share

   
   
10. ZHANG Y, Wu J, Cai X, Jiang K, et al
    Response to Zun-Jiang Zhao et al., "Comment on 'Nevus-associated acral melanoma has lower risk of recurrence and mortality than de novo acral melanoma'.".
    J Am Acad Dermatol. 2026 May 29:S0190-9622(26)02733.
    

    >> Share

    
    

    
    J Clin Oncol

11. KHATTAK A, Carlino MS, Meniawy T, Ansstas G, et al
    Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study.
    J Clin Oncol. 2026 Jun 1:101200JCO2600835. doi: 10.1200/JCO-26-00835.
    

    >> Share

    
    

    
    J Invest Dermatol

12. NARAYANA RVL, Lanier AL, Wajapeyee N, Gupta R, et al
    Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells.
    J Invest Dermatol. 2026 May 30:S0022-202X(26)01033.
    

    >> Share

    
    

    
    Melanoma Res

13. KYRIAKOPOULOS A, Kyriakopoulos V, Vourlakou C, Balasis S, et al
    A rare case of fully regressive melanoma in the absence of metastasis.
    Melanoma Res. 2026 Jun 2. doi: 10.1097/CMR.0000000000001111.
    

    >> Share

    
    

    
    Ophthalmol Retina

14. BOUHOUT S, Zhang Z, Suh JH, Singh AD, et al
    Low-dose Brachytherapy for Choroidal Melanoma: A Preliminary Report.
    Ophthalmol Retina. 2026 May 29:S2468-6530(26)00241.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share